The axillary nodal status is accepted universally as the most powerful prognostic tool available for early stage breast cancer. Breast cancer patients routinely undergo surgical staging of the axilla because other primary tumor features are inadequate in predicting the presence versus absence of nodal positivity [1][2][3]. The status of the axillary lymph nodes also guides treatment options and adjuvant therapies. The removal of level I and level II lymph nodes at axillary node dissection (ALND) is the most accurate method to assess nodal status, and it is the universal standard. ALND is associated with several adverse long-term sequelae including lymphedema, the disruption of nerves in the axilla, chronic shoulder pain, weakness, and joint dysfunction. Additionally, the survival advantage of ALND has been challenged, and less morbid methods of evaluating the axillary nodal basin have been sought.Breast cancer spreads from the tumor bed to one or a few lymph nodes before it spreads to other axillary nodes. These sentinel nodes can be identified and surgically excised for histological analysis. Lymphatic mapping with sentinel lymph node biopsy (SLNB) has emerged as an effective method of detecting axillary metastases. Veronesi and colleagues [4] randomly assigned 516 women with early stage breast cancer to either SLNB and ALND or SLNB alone (ALND was performed only for axillary metastases in the SLNB-alone arm). The authors demonstrated that SLNB was